These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10447417)

  • 1. Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection.
    Mihm S; Monazahian M; Grethe S; Fechner C; Ramadori G; Thomssen R
    J Med Virol; 1999 Jul; 58(3):227-34. PubMed ID: 10447417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
    Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
    J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.
    Shen C; Hu T; Shen L; Gao L; Xie W; Zhang J
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1898-903. PubMed ID: 17914967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
    J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
    Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
    J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
    Amanzada A; Goralczyk A; Moriconi F; Blaschke M; Schaefer IM; van Thiel D; Mihm S; Ramadori G
    Dig Dis Sci; 2011 Nov; 56(11):3296-304. PubMed ID: 21994136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
    Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio.
    Mihm S; Hartmann H; Fayyazi A; Ramadori G
    Dig Dis Sci; 1996 Jun; 41(6):1256-64. PubMed ID: 8654161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
    Nakagawa M; Sakamoto N; Ueyama M; Mogushi K; Nagaie S; Itsui Y; Azuma S; Kakinuma S; Tanaka H; Enomoto N; Watanabe M
    J Gastroenterol; 2010 Jun; 45(6):656-65. PubMed ID: 20112032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NS5a gene of hepatitis C virus in patients treated with interferon-alpha.
    McKechnie VM; Mills PR; McCruden EA
    J Med Virol; 2000 Apr; 60(4):367-78. PubMed ID: 10686018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study.
    Amanzada A; Goralczyk AD; Schneider S; Moriconi F; Lindhorst A; Mihm S; Van Thiel DH; Ramadori G
    Digestion; 2012; 86(3):218-27. PubMed ID: 22964578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection.
    Yoshioka K; Kobayashi M; Orito E; Watanabe K; Yano M; Sameshima Y; Kusakabe A; Hirofuji H; Fuji A; Kuriki J; Arao M; Murase K; Mizokami M; Kakumu S
    J Viral Hepat; 2001 Nov; 8(6):421-9. PubMed ID: 11703573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA.
    Arase Y; Ikeda K; Chayama K; Murashima N; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Kobayashi M; Kumada H
    Intern Med; 1999 Jun; 38(6):461-6. PubMed ID: 10411349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.
    Yoon J; Lee JI; Baik SK; Lee KH; Sohn JH; Lee HW; Namkung J; Chang SJ; Choi JW; Kim HW; Yeh BI
    World J Gastroenterol; 2007 Dec; 13(46):6236-42. PubMed ID: 18069766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
    Cappiello G; Abbate I; Lo Iacono O; Longo R; Solmone M; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxi A; Ippolito G; Capobianchi MR
    Antivir Ther; 2003 Apr; 8(2):105-10. PubMed ID: 12741622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.